RAPT Therapeutics (NasdaqGM:RAPT) Earnings Call Presentation

THE SCIENCE TO OVERCOME INFLAMMATION Phase 2 Topline Results of RPT904 (JYB1904) in Chronic Spontaneous Urticaria OCTOBER 20, 2025 Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected timing of clinical trials and the availability of data therefrom; expectations regarding regulatory interactions; the therapeutic a ...